REFERENCES
1. Maude SL, Frey N, Shaw PA, et al. Chimeric Antigen Receptor T Cells
for Sustained Remissions in Leukemia. N Engl J Med.2014;371:1507-1517.
2. Wang J, Hu Y, Yang S, et al. Role of Fluorodeoxyglucose Positron
Emission Tomography/Computed Tomography in Predicting the Adverse
Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with
Non-Hodgkin Lymphoma. Biol Blood Marrow Transplant.2019;25:1092-1098.
3. Danylesko I, Shouval R, Shem-Tov N, et al. Immune imitation of tumor
progression after anti-CD19 chimeric antigen receptor T cells treatment
in aggressive B-cell lymphoma. Bone Marrow Transplant. 2020;18-
doi:10.1038/s41409-020-01156-y.
4. Denton CC, Gange WS, Abdel-Azim H, et al. Bilateral retinal
detachment after chimeric antigen receptor T-cell therapy. Blood
Adv. 2020;4:2158-2162.
5. Huang J, Rong L, Wang E, Fang Y. Pseudoprogression of extramedullary
disease in relapsed acute lymphoblastic leukemia after CAR T-cell
therapy. Immunotherapy 2021;13:5-10.